Research Analysts Set Expectations for argenx Q1 Earnings

argenx SE (NASDAQ:ARGX) – Equities researchers at William Blair issued their Q1 2026 earnings estimates for argenx in a research note issued to investors on Monday, March 17th. William Blair analyst M. Minter anticipates that the company will earn $6.06 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx’s Q2 2026 earnings at $6.23 EPS and Q3 2026 earnings at $7.02 EPS.

ARGX has been the topic of a number of other research reports. Oppenheimer raised their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Guggenheim raised their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, March 10th. HC Wainwright raised their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Evercore ISI raised their target price on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Truist Financial reaffirmed a “buy” rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Trading Down 0.5 %

Shares of ARGX opened at $611.18 on Wednesday. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The stock has a market cap of $37.14 billion, a P/E ratio of -694.52 and a beta of 0.59. The stock’s 50-day moving average price is $636.83 and its two-hundred day moving average price is $598.22.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Institutional Investors Weigh In On argenx

A number of hedge funds and other institutional investors have recently bought and sold shares of ARGX. GeoWealth Management LLC increased its position in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new position in argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC lifted its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in argenx during the fourth quarter worth approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of argenx during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.